{
    "clinical_study": {
        "@rank": "114199", 
        "acronym": "AGTs-MDD", 
        "arm_group": [
            {
                "arm_group_label": "Algorithm Guided Treatment (AGT)", 
                "arm_group_type": "Active Comparator", 
                "description": "Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first."
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "arm_group_type": "Active Comparator", 
                "description": "This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare treatment outcomes between measurement based\n      Algorithm Guided Treatment and Treatment As Usual strategies in a Chinese population with\n      major depressive disorder."
        }, 
        "brief_title": "Algorithm Guided Treatment Strategies for Major Depressive Disorder", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The AGT arm includes a 2-step medication monotherapy and a combination treatment algorithm.\n      The first step (level 1) includes two medication monotherapy options: escitalopram and\n      mirtazapine. For those participants who don't remit with the initial intervention after up\n      to 6 to 12-week treatment, the second step (level 2) with a variety of treatment options\n      will be provided. In level 2 intervention, a switch strategy for those who don't remit with\n      escitalopram will be switched to mirtazapine, or for those who don't remit with mirtazapine\n      will be switched to escitalopram, combination strategy (i.e. escitalopram plus mirtazapine)\n      and augmentation strategy (i.e. escitalopram or mirtazapine plus either rTMS or mECT).\n      Participants who don't get remission in level 1 intervention will be encouraged to enter\n      level 2 interventions based on intend-to-treatment principle. The TAU arm as control\n      intervention is performed using the psychiatrist's individual discretion based on his/her\n      expertise and knowledge.\n\n      Participants will be recruited consecutively in 8 psychiatric settings across China and\n      randomized into any of the two initial interventions of AGT or TAU arm. Follow-up interviews\n      will be performed monthly for all participants who finish any acute treatment of AGT or TAU.\n      The follow-up period will last up to 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)\n             criteria for single or recurrent nonpsychotic major depressive disorder\n\n          -  Age 18-75\n\n          -  Written informed consent completed\n\n          -  Scores 14 or higher on the 17-item Hamilton Depression Rating Scale\n\n          -  Initial treatment with escitalopram or mirtazapine or other antidepressants is\n             clinically appropriate\n\n        Exclusion Criteria:\n\n          -  History of bipolar disorder\n\n          -  Concurring psychotic disorders\n\n          -  Scores 3 or higher on item 3 (suicidal) of HRSD-17\n\n          -  History of nonresponse to an adequate trial of escitalopram and/or mirtazapine\n\n          -  Has general medical condition, which contraindicates any leve 1 or 2 treatment option\n\n          -  Is on concomitant medication, which contraindicates any leve 1 or 2 treatment option\n\n          -  Any contraindication for mECT or rTMS\n\n          -  Is pregnant or breast feeding or is planning to get pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1080", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764867", 
            "org_study_id": "2012BAI01B04-MDD", 
            "secondary_id": "2012BAI01B04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Algorithm Guided Treatment (AGT)", 
                "description": "Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.", 
                "intervention_name": "Escitalopram", 
                "intervention_type": "Drug", 
                "other_name": "Lexapro"
            }, 
            {
                "arm_group_label": "Algorithm Guided Treatment (AGT)", 
                "description": "Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.", 
                "intervention_name": "Mirtazapine", 
                "intervention_type": "Drug", 
                "other_name": "Remeron"
            }, 
            {
                "arm_group_label": "Algorithm Guided Treatment (AGT)", 
                "description": "Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.", 
                "intervention_name": "modified electroconvulsive therapy", 
                "intervention_type": "Other", 
                "other_name": "mECT"
            }, 
            {
                "arm_group_label": "Algorithm Guided Treatment (AGT)", 
                "description": "Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.", 
                "intervention_name": "repetitive transcranial magnetic stimulation", 
                "intervention_type": "Other", 
                "other_name": "rTMS"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Fluoxetine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Citalopram", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Escitalopram", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Paroxetine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Sertraline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Fluvoxamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Venlafaxine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Duloxetine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Mirtazapine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Bupropion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment As Usual (TAU)", 
                "description": "Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.", 
                "intervention_name": "Trazodone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trazodone", 
                "Fluvoxamine", 
                "Citalopram", 
                "Fluoxetine", 
                "Paroxetine", 
                "Sertraline", 
                "Venlafaxine", 
                "Duloxetine", 
                "Mianserin", 
                "Bupropion", 
                "Mirtazapine", 
                "Dexetimide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "major depressive disorder", 
            "algorithm guided treatment", 
            "treatment as usual", 
            "escitalopram", 
            "mirtazapine", 
            "transcranial magnetic stimulation (rTMS)", 
            "modified electroconvulsive therapy (mECT)", 
            "remission", 
            "relapse", 
            "quality of life"
        ], 
        "lastchanged_date": "January 8, 2013", 
        "location": {
            "contact": {
                "email": "wu_zhiguo@yahoo.com.cn", 
                "last_name": "Zhiguo Wu, M.D.", 
                "phone": "862134289888", 
                "phone_ext": "3528"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200030"
                }, 
                "name": "Shanghai Mental Health Center"
            }, 
            "investigator": {
                "last_name": "Yiru Fang, Ph.D., M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Algorithm Guided Treatment Strategies for Major Depressive Disorder", 
        "other_outcome": {
            "description": "Relapse rate will be measured  at the end of 6 months after remission.", 
            "measure": "Relapse rate", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_contact": {
            "email": "wu_zhiguo@yahoo.com.cn", 
            "last_name": "Zhiguo Wu, M.D.", 
            "phone": "862134289888", 
            "phone_ext": "3528"
        }, 
        "overall_official": {
            "affiliation": "Shanghai Mental Health Center", 
            "last_name": "Yiru Fang, Ph.D., M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Acute treatment will last at least 6 weeks if remission occurs, or up to 12 weeks. Endpoint total score in HRSD-17 at up to 12 weeks will be measured to determine wether remission occurs.", 
            "measure": "Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score \u2264 7", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764867"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Mental Health Center", 
            "investigator_full_name": "Yiru FANG", 
            "investigator_title": "Ph.D., Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score \u2264 5", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Self-report and clinician rating frequency and intensity of adverse events will be measured at up to 12 weeks.", 
                "measure": "Frequency and intensity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Change from baseline in 6-item Quality of life Inventory will be measured at up to 12 weeks.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Shanghai Mental Health Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Mental Health Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}